Jinweike Bio

Beijing Jinweike Biotechnology is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the research and development of innovative vaccines. The company leverages advanced recombinant protein and genetic engineering platforms to develop preventive treatments for infectious diseases. Jinweike is most recognized for its late-stage recombinant rabies vaccine and its contributions to COVID-19 vaccine development. As a key subsidiary of Walvax Biotechnology, the company benefits from significant industrial resources and manufacturing capabilities. Their pipeline focuses on addressing public health challenges through high-efficacy, low-side-effect biologic products. The company continues to expand its technological reach into mRNA and other next-generation vaccine modalities.